Methods, compositions and kits for detection and analysis of antibiotic-resistant bacteria

• US 8,017,337 B2
• Filed: 04/18/2008
• Issued: 09/13/2011
• Est. Priority Date: 04/19/2007
• Status: Expired due to Fees

• Current Assignee: Molecular Detection Inc.
• Original Assignee: Molecular Detection Inc.
• Inventors: Paitan, Yosef
• Primary Examiner(s): WOOLWINE, SAMUEL C
• Application Number:
  US12/106,137
• Publication Number:
  US 20090081663A1
• Time in Patent Office: 1,243 Days
• Field of Search: None
• US Class Current: 435/6.12
• CPC Class Codes: C12Q 1/689 for bacteria
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays

Abstract

The present invention relates generally to detection of antibiotic-resistant bacteria in a sample. In particular, the invention provides methods, compositions and kits for detecting and analyzing methicillin-resistant Staphylococcus aureus (MRSA) and other methicillin-resistant bacteria in a sample.

Claims

1. A method of detecting methicillin-resistant S. aureus (MRSA) in a sample, wherein said sample contains one or a mixture of bacterial species, said method comprising:

(a) providing a first set of primers, wherein said first set of primers are complementary to at least a portion of a mecA polynucleotide sequence;

(b) providing a second set of primers, wherein said second set of primers are complementary to at least a portion of a bridging region;

(c) providing a third set of primers, wherein said third set of primers are complementary to at least a portion of an S. aureus-specific polynucleotide sequence, and wherein said S. aureus-specific polynucleotide sequence is not an orfX polynucleotide;

(d) combining said first, second and third set of primers with said sample in a reaction mixture;

(e) performing a multi-cycle amplification reaction with said reaction mixture;

(f) determining cycle numbers of appearance of each of said mecA, bridging region and S. aureus-specific polynucleotide sequences,

(g) comparing said cycle numbers of appearance of said mecA, bridging region, and S. aureus-specific polynucleotide sequences to each other,

wherein if said mecA polynucleotide sequence has a cycle number of appearance that is substantially the same as that of either said bridging region sequence or said S. aureus-specific polynucleotide sequence, then MRSA is present in said sample.

2. A method according to claim 1, wherein said first set of primers comprises at least one of SEQ ID NOs:

10-11.

3. A method according to claim 1, wherein said second set of primers comprises at least one of SEQ ID NOs:

2-8.

4. A method according to claim 1, wherein said third set of primers comprises at least one of SEQ ID NOs:

13-14 and 18-19.

5. A method according to claim 1, wherein said amplification reaction is a real-time polymerase chain reaction (PCR).

6. A method according to claim 1, said method further comprising:

(h) contacting said sample with primers complementary to at least a portion of a human gene polynucleotide sequence;

(i) amplifying said human gene polynucleotide sequence; and

(j) detecting said amplified human gene polynucleotide sequence.

7. A method according to claim 1, wherein said S. aureus-specific polynucleotide sequence is at least a portion of a gene, which is a member selected from nuc and Sa442.

8. A method according to claim 7, wherein said gene is nuc.

9. A method according to claim 7, wherein said gene is Sa442.

10. A method of detecting methicillin-resistant S. aureus (MRSA) in a sample, wherein said sample contains one or a mixture of bacterial species, said method comprising:

(a) determining cycle number of appearance of a mecA polynucleotide sequence amplified from said sample;

(b) determining cycle number of appearance of a bridging region polynucleotide sequence amplified from said sample; and

(c) determining cycle number of appearance of an S. aureus-specific polynucleotide sequence amplified from said sample, wherein said S. aureus-specific polynucleotide sequence is not an orfX polynucleotide sequence,

(d) comparing said cycle numbers of appearance of said mecA, bridging region, and S. aureus-specific polynucleotide sequences to each other,

wherein if said cycle number of appearance of each of said mecA polynucleotide, said bridging region polynucleotide, and said S. aureus-specific polynucleotide sequences are substantially the same, then MRSA is present in said sample.

11. A method according to claim 10, wherein said mecA polynucleotide is amplified from said sample using a first set of primers, and wherein a majority of said first set of primers are complementary to at least a portion of said mecA polynucleotide.

12. A method according to claim 11, wherein said first set of primers comprises at least one of SEQ ID NOs. 10-11.

13. A method according to claim 10, wherein said bridging region polynucleotide is amplified from said sample using a second set of primers, and wherein a majority of said second set of primers are complementary to at least a portion of said bridging region polynucleotide.

14. A method according to claim 13, wherein said second set of primers comprises at least one of SEQ ID NOs. 2-8.

15. A method according to claim 10, wherein said S. aureus-specific polynucleotide is amplified from said sample using a third set of primers, and wherein a majority of said third set of primers are complementary to at least a portion of said S. aureus-specific polynucleotide.

16. A method according to claim 15, wherein said third set of primers comprises at least one of SEQ ID NOs. 13-14 and 18-19.

17. A method according to claim 10, wherein said S. aureus-specific polynucleotide is at least a portion of a gene, which is a member selected from nuc and Sa442.

18. A method according to claim 17, wherein said S. aureus-specific polynucleotide is nuc.

19. A method according to claim 17, wherein said S. aureus-specific polynucleotide is Sa442.

20. A method according to claim 10, said method further comprising:

(e) contacting said sample with primers complementary to at least a portion of a human gene polynucleotide sequence;

(f) amplifying said human gene polynucleotide sequence; and

(g) detecting said amplified human gene polynucleotide sequence.

21. A method according to claim 20, wherein said human gene polynucleotide sequence comprises at least a portion of a housekeeping gene.

22. A method according to claim 20, wherein said human gene polynucleotide sequence comprises at least a portion of a β

-globin gene.

23. A method according to claim 10, wherein steps (a), (b), and (c) are performed simultaneously.

24. A method according to claim 10, wherein steps (a), (b), and (c) are performed sequentially in any order.

25. A method according to claim 10, wherein steps (a), (b), and (c) are performed in an identical aliquot of said sample.

26. A method according to claim 10, wherein steps (a), (b), and (c) are performed in different aliquots of said sample.

27. A method according to claim 10, wherein if said mecA polynucleotide is present in said sample and said S. aureus-specific polynucleotide is present in said sample but said bridging region polynucleotide is not present in said sample, then said sample either comprises a strain of methicillin-resistant Staphylococcus aureus undetectable by bridging region primers or comprises a mixture of methicillin-sensitive Staphylococcus aureus and a second non-Staphylococcus aureus bacteria that is methicillin-resistant.

28. A kit for identifying MRSA in a sample, said kit comprising:

(a) a first set of primers complementary to at least a portion of a mecA polynucleotide sequence;

(b) a second set of primers complementary to at least a portion of a bridging sequence;

(c) a third set of primers complementary to at least a portion of an S. aureus-specific polynucleotide sequence, wherein said S. aureus-specific polynucleotide sequence is not an orfX polynucleotide; and

at least one member selected from;

a DNA polymerase enzyme, dNTPs, magnesium and a stabilizer.

29. A method of detecting an antibiotic-resistant bacterial strain in a sample, wherein said sample contains one or a mixture of bacterial species, said method comprising:

(a) providing a first set of primers, wherein said first set of primers are capable of producing a first amplification product from at least a portion of a gene, wherein said gene confers antibiotic-resistance;

(b) providing a second set of primers, wherein said second set of primers are capable of producing a second amplification product from at least a portion of a bridging region;

(c) providing a third set of primers, wherein said third set of primers are capable of producing a third amplification product from at least a portion of a bacterial strain-specific polynucleotide sequence;

(d) combining said first, second and third set of primers with said sample in a reaction mixture;

(e) performing a multi-cycle amplification reaction with said reaction mixture;

(f) determining cycle numbers of appearance of each of said first, second and third amplification products,

(g) comparing said cycle numbers of appearance of said first, second and third amplification products to each other,

wherein if said cycle numbers of appearance of said first, second and third amplification products are substantially the same, then an antibiotic-resistant bacterial strain is present in said sample.

30. A method according to claim 29, wherein said gene confers resistance to vancomycin.

31. A method according to claim 29, wherein said gene confers resistance to methicillin.

32. A method according to claim 29, wherein said bacterial strain-specific polynucleotide sequence is an S. aureus-specific polynucleotide sequence.

33. A method according to claim 29, wherein said bridging region comprises a polynucleotide sequence that is a member selected from SEQ ID NOs:

2-8.